TEL. 03-3353-8111
〒162-8666 8-1, Kawada-cho, Shinjuku-ku, Tokyo
The Department of Chemotherapy and Palliative Care is responsible for chemotherapy and palliative care for cancer.
Unlike conventional organ-specific chemotherapy using cytotoxic anticancer drugs, cancer treatment with molecular targeted drugs, which have been rapidly developed in recent years, is now universally applied to various types of cancer tumors. Our department is also responsible for the treatment of a wide range of cancers, including solid tumors, mainly the five major cancers, cancers of unknown primary and cancers involving multiple organs, for which the responsible department tends to be unclear, in cooperation with other departments.
In addition, as a recent global trend, it is becoming generally recognized that palliative care should be initiated at the time of cancer diagnosis. To achieve holistic cancer care, which is the basic philosophy of our Cancer Center, it is essential to enhance palliative cancer care and to collaborate with local medical institutions. Our department is working to alleviate the suffering of cancer patients in the hospital through the activities of the Outpatient Cancer Palliative Care Clinic and the Palliative Care Team. Also, we are actively promoting regional cooperation by using a bus and home medical care.
Lectures in our department focus on human relations education (dialogue with self: 2 years, palliative medicine: 4 years, how doctors should be in terminal care: 6 years), basic theory of chemotherapy, general theory of clinical chemotherapy, palliative care, treatment of total pain (block 8), and in elective training, students learn the basic attitude to face cancer with patients as a human being before being a medical student.
Residents will acquire basic knowledge and experience in cancer chemotherapy and palliative care through our unique training program and with a renewed awareness of their great mission and responsibility as physicians, aiming to become robust physicians who can manage seamless holistic cancer care. We will ensure that students acquire the training results necessary to take the examinations for cancer specialists, such as "Certified Doctor of Cancer Therapy" by the Japanese Organization of Medical Examiners for Cancer Therapy, "Specialist in Cancer Drug Therapy" by the Japanese Society of Clinical Oncology, and "Palliative Medicine Doctor" by the Japanese Society of Palliative Medicine.
(1) Search for genes that regulate sensitivity to anti-cancer drugs
(2) Search for genes that determine sensitivity to anti-cancer drugs
(3) Gene analysis from peripheral blood free cancer cells (CTCs)
(4) Immune monitoring during chemotherapy
(5) Search for genetic background factors of patients who respond well to chemotherapy
(6) Investigation of methodologies for tailor-made chemotherapy
Hidekazu Kuramochi
Go Nakajima
In anticancer drug therapy (chemotherapy), large individual differences are observed in treatment efficacy and adverse drug reactions (side effects). In the past, chemotherapy has been administered by first administering the anticancer drug that is statistically most effective based on past clinical trial data, continuing treatment when it is effective and causes few side effects and switching to a different anticancer drug when it is ineffective or causes too many side effects. However, individual patients differ in drug response due to various factors such as body size, age, organ function, presence or absence of complications, previous treatment history, concomitant medications, and genetic background. In order to eliminate such individual differences as much as possible, our department is actively promoting translational research to establish personalized medicine based on scientific evidence.
〒162-8666
8-1, Kawada-cho, Shinjuku-ku, Tokyo
TEL +81-3-3353-8111